Does the media favor BEAM or DNLI?

In the previous week, Beam Therapeutics had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 14 mentions for Beam Therapeutics and 11 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.78 beat Beam Therapeutics' score of 0.50 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNLI or BBIO?

In the previous week, BridgeBio Pharma had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 11 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.78 beat BridgeBio Pharma's score of 0.70 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNLI or AXSM?

In the previous week, Axsome Therapeutics had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 12 mentions for Axsome Therapeutics and 11 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.78 beat Axsome Therapeutics' score of 0.75 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNLI or ELAN?

In the previous week, Denali Therapeutics had 6 more articles in the media than Elanco Animal Health. MarketBeat recorded 11 mentions for Denali Therapeutics and 5 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.16 beat Denali Therapeutics' score of 0.78 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RDY or DNLI?

Denali Therapeutics has a consensus price target of $34.75, suggesting a potential upside of 31.23%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Denali Therapeutics 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.81

Does the media favor RDY or DNLI?

In the previous week, Denali Therapeutics had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 11 mentions for Denali Therapeutics and 5 mentions for Dr. Reddy's Laboratories. Denali Therapeutics' average media sentiment score of 0.78 beat Dr. Reddy's Laboratories' score of -0.18 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Denali Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Denali Therapeutics (DNLI) Competitors

$26.48 +0.80 (+3.12%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$26.20 -0.28 (-1.06%)

As of 07/13/2026 07:49 PM Eastern

Compare

DNLI vs. BEAM, BBIO, AXSM, ELAN, and RDY

Should you buy Denali Therapeutics stock or one of its competitors? MarketBeat compares Denali Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Denali Therapeutics include Beam Therapeutics (BEAM), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does Denali Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Beam Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	22.82	-$79.99M	-$0.68	N/A
Denali Therapeutics	$330.53M	12.71	-$512.54M	-$2.88	N/A

Beam Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

In the previous week, Beam Therapeutics had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 14 mentions for Beam Therapeutics and 11 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.78 beat Beam Therapeutics' score of 0.50 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Denali Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics presently has a consensus target price of $46.85, indicating a potential upside of 51.12%. Denali Therapeutics has a consensus target price of $34.75, indicating a potential upside of 31.23%. Given Beam Therapeutics' higher possible upside, equities research analysts clearly believe Beam Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Denali Therapeutics	N/A	-52.20%	-43.86%

Summary

Beam Therapeutics beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to BridgeBio Pharma?

Denali Therapeutics (NASDAQ:DNLI) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Denali Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Denali Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 11 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.78 beat BridgeBio Pharma's score of 0.70 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	12.71	-$512.54M	-$2.88	N/A
BridgeBio Pharma	$502.08M	32.41	-$724.93M	-$3.74	N/A

Denali Therapeutics currently has a consensus target price of $34.75, suggesting a potential upside of 31.23%. BridgeBio Pharma has a consensus target price of $94.63, suggesting a potential upside of 13.90%. Given Denali Therapeutics' higher probable upside, equities research analysts plainly believe Denali Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Denali Therapeutics beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to Axsome Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Denali Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Denali Therapeutics' return on equity of -52.20% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Denali Therapeutics presently has a consensus price target of $34.75, suggesting a potential upside of 31.23%. Axsome Therapeutics has a consensus price target of $259.05, suggesting a potential upside of 13.48%. Given Denali Therapeutics' higher possible upside, equities research analysts plainly believe Denali Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

Denali Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Axsome Therapeutics has higher revenue and earnings than Denali Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	12.71	-$512.54M	-$2.88	N/A
Axsome Therapeutics	$638.50M	18.40	-$183.17M	-$3.73	N/A

In the previous week, Axsome Therapeutics had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 12 mentions for Axsome Therapeutics and 11 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.78 beat Axsome Therapeutics' score of 0.75 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Denali Therapeutics and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Elanco Animal Health?

Denali Therapeutics (NASDAQ:DNLI) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Denali Therapeutics currently has a consensus target price of $34.75, indicating a potential upside of 31.23%. Elanco Animal Health has a consensus target price of $28.55, indicating a potential upside of 13.61%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Denali Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Denali Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Elanco Animal Health	-4.95%	7.42%	3.66%

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Elanco Animal Health has higher revenue and earnings than Denali Therapeutics. Elanco Animal Health is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	12.71	-$512.54M	-$2.88	N/A
Elanco Animal Health	$4.72B	2.66	-$232M	-$0.50	N/A

In the previous week, Denali Therapeutics had 6 more articles in the media than Elanco Animal Health. MarketBeat recorded 11 mentions for Denali Therapeutics and 5 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.16 beat Denali Therapeutics' score of 0.78 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

Summary

Denali Therapeutics and Elanco Animal Health tied by winning 8 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Denali Therapeutics has a consensus price target of $34.75, suggesting a potential upside of 31.23%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

In the previous week, Denali Therapeutics had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 11 mentions for Denali Therapeutics and 5 mentions for Dr. Reddy's Laboratories. Denali Therapeutics' average media sentiment score of 0.78 beat Dr. Reddy's Laboratories' score of -0.18 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Denali Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.02	$456M	$0.58	22.30
Denali Therapeutics	$330.53M	12.71	-$512.54M	-$2.88	N/A

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Denali Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Denali Therapeutics	N/A	-52.20%	-43.86%

Summary

Denali Therapeutics beats Dr. Reddy's Laboratories on 10 of the 17 factors compared between the two stocks.

Get Denali Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNLI vs. The Competition

Export

Metric	Denali Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.08B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-9.19	20.85	27.11	24.26
Price / Sales	12.71	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	3.83	8.49	10.75	6.29
Net Income	-$512.54M	$23.83M	$3.58B	$330.66M
7 Day Performance	0.65%	-3.56%	-2.06%	-1.32%
1 Month Performance	22.25%	6.31%	3.32%	-0.64%
1 Year Performance	80.26%	48.30%	26.36%	19.08%

Denali Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNLI Denali Therapeutics	3.2886 of 5 stars	$26.48 +3.1%	$34.75 +31.2%	+82.4%	$4.08B	$330.53M	N/A	430	News Coverage Analyst Forecast
BEAM Beam Therapeutics	3.3734 of 5 stars	$35.32 +1.5%	$46.83 +32.6%	+46.5%	$3.58B	$139.74M	N/A	510	Gap Down
BBIO BridgeBio Pharma	3.1076 of 5 stars	$77.75 +0.7%	$92.90 +19.5%	+78.8%	$15.12B	$502.08M	N/A	400	Analyst Forecast Insider Trade
AXSM Axsome Therapeutics	3.5238 of 5 stars	$242.60 -0.7%	$258.95 +6.7%	+109.5%	$12.57B	$638.50M	N/A	380
ELAN Elanco Animal Health	3.9076 of 5 stars	$25.12 +0.5%	$28.55 +13.6%	+68.7%	$12.49B	$4.72B	N/A	9,400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNLI) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, BBIO, AXSM, ELAN, and RDY

How does Denali Therapeutics compare to Beam Therapeutics?

Summary

How does Denali Therapeutics compare to BridgeBio Pharma?

Summary

How does Denali Therapeutics compare to Axsome Therapeutics?

Summary

How does Denali Therapeutics compare to Elanco Animal Health?

Summary

How does Denali Therapeutics compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, BBIO, AXSM, ELAN, and RDY

How does Denali Therapeutics compare to Beam Therapeutics?

Which has better earnings & valuation, BEAM or DNLI?

Which has more risk & volatility, BEAM or DNLI?

Does the media favor BEAM or DNLI?

Do analysts prefer BEAM or DNLI?

Do institutionals & insiders have more ownership in BEAM or DNLI?

Is BEAM or DNLI more profitable?

Summary

How does Denali Therapeutics compare to BridgeBio Pharma?

Is DNLI or BBIO more profitable?

Which has more volatility and risk, DNLI or BBIO?

Do institutionals and insiders have more ownership in DNLI or BBIO?

Does the media prefer DNLI or BBIO?

Which has better valuation and earnings, DNLI or BBIO?

Do analysts rate DNLI or BBIO?

Summary

How does Denali Therapeutics compare to Axsome Therapeutics?

Do institutionals & insiders hold more shares of DNLI or AXSM?

Is DNLI or AXSM more profitable?

Do analysts rate DNLI or AXSM?

Which has more risk & volatility, DNLI or AXSM?

Which has higher earnings & valuation, DNLI or AXSM?

Does the media prefer DNLI or AXSM?

Summary

How does Denali Therapeutics compare to Elanco Animal Health?

Do analysts rate DNLI or ELAN?

Is DNLI or ELAN more profitable?

Do institutionals & insiders hold more shares of DNLI or ELAN?

Which has stronger earnings & valuation, DNLI or ELAN?

Does the media refer more to DNLI or ELAN?

Which has more risk & volatility, DNLI or ELAN?

Summary

How does Denali Therapeutics compare to Dr. Reddy's Laboratories?

Do analysts prefer RDY or DNLI?

Which has more volatility & risk, RDY or DNLI?

Does the media favor RDY or DNLI?

Which has preferable earnings & valuation, RDY or DNLI?

Do institutionals & insiders have more ownership in RDY or DNLI?

Is RDY or DNLI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools